FDA Inspection 1211387 — Philip R. Clingan
The FDA completed an inspection of Philip R. Clingan on July 20, 2023 in Wollongong. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 20, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Wollongong (Australia)
Additional Details
Clinical Investigator (CI)